Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly EBITDA Margin of 14.83% in Q4 2025, down 152.62% quarter-over-quarter from 5.87% in Q3 2025, and up 2122.0% on a YoY basis from 0.67% in Q4 2024.
Sonoma Pharmaceuticals (SNOA) EBITDA Margin (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' EBITDA Margin history runs 16 years deep, the most recent figure standing at 14.83% for Q4 2025.
- In Q4 2025, EBITDA Margin rose 2122.0% year-over-year to 14.83%; the TTM figure through Dec 2025 stood at 11.32% (up 2789.0% YoY), while the FY2025 annual figure was 35.76%, down 326.0% from the prior year.
- EBITDA Margin was 14.83% for Q4 2025 at Sonoma Pharmaceuticals, down from 5.87% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 5.87% in Q3 2025 to a low of 185.63% in Q1 2021.
- Historically, EBITDA Margin has averaged 40.54% across 5 years, with a median of 27.29% in 2023.
- The sharpest annual moves came in 2021 and 2023: EBITDA Margin slumped 11086 bps in 2021, then jumped 9859 bps in 2023.
- A 5-year view of EBITDA Margin shows it stood at 34.77% in 2021, then plunged by 66 bps to 57.88% in 2022, then soared by 69 bps to 18.13% in 2023, then sank by 99 bps to 36.05% in 2024, then jumped by 59 bps to 14.83% in 2025.
- The last three EBITDA Margin figures came in at 14.83% (Q4 2025), 5.87% (Q3 2025), and 10.83% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn | -14.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.83% |
| Sep 30, 2025 | -5.87% |
| Jun 30, 2025 | -10.83% |
| Mar 31, 2025 | -15.93% |
| Dec 31, 2024 | -36.05% |
| Sep 30, 2024 | -33.61% |
| Jun 30, 2024 | -59.69% |
| Mar 31, 2024 | -28.12% |
| Dec 31, 2023 | -18.13% |
| Sep 30, 2023 | -62.14% |
| Jun 30, 2023 | -26.47% |
| Mar 31, 2023 | -18.25% |
| Dec 31, 2022 | -57.88% |
| Sep 30, 2022 | -31.55% |
| Jun 30, 2022 | -23.90% |
| Mar 31, 2022 | -116.84% |
| Dec 31, 2021 | -34.77% |
| Sep 30, 2021 | -8.92% |
| Jun 30, 2021 | -21.47% |
| Mar 31, 2021 | -185.63% |